Serotonin Syndrome Due to Co-Administration of Linezolid and Methadone

Total Page:16

File Type:pdf, Size:1020Kb

Serotonin Syndrome Due to Co-Administration of Linezolid and Methadone Le Infezioni in Medicina, n. 3, 263-266, 2017 CASE REPORT 263 Serotonin syndrome due to co-administration of linezolid and methadone Antonio Mastroianni1, Gianfranco Ravaglia2 1U.O. Malattie Infettive, Presidio Ospedaliero, “G.B. Morgagni - L. Pierantoni”, Forlì, Italy; 2U.O. Farmacia, Presidio Ospedaliero “G.B. Morgagni - L. Pierantoni”, Forlì, Italy SUMMARY Serotonin syndrome (SS), a potentially life-threatening verity from mild to life-threatening. To our knowledge, adverse drug reaction caused by excessive serotoner- we present the first reported case of SS associated with gic agonism in central and peripheral nervous system linezolid and methadone with a brief review of the lit- serotonergic receptors, may be caused by a single drug erature. or a combination of drugs with serotonergic activity. The syndrome results in a variety of mental, autonom- Keywords: serotonin syndrome, linezolid, methadone, ic and neuromuscular changes, which can range in se- methicillin-resistant Staphylococcus aureus. n INTRODUCTION methadone. This serious adverse interaction be- tween linezolid and methadone inducing SS was erotonin syndrome (SS) is a toxic state caused reported in a drug-addict HIV-positive man with Smainly by excessive serotonergic activity in sepsis, osteomyelitis and multiple muscle abscess- the nervous system, nearly always caused by a es and metastatic skin abscesses caused by meth- drug interaction involving two or more “seroto- icillin-resistant Staphylococcus aureus (MRSA), un- nergic” drugs [1]. These include serotonin pre- der combined antibiotic treatment. cursors, serotonin agonists, serotonin releasers, serotonin reuptake inhibitors, monoaminoxidase inhibitors (MAOIs) and some herbal medicines. n CASE REPORT Linezolid is a weak, nonselective, reversible in- hibitor of MAOIs, and potentially may interact A 39-year-old drug-addict male was admitted to with MAOIs and adrenergic and serotonergic our department with fever (up to 39.5°C) and a agents. SS has been reported in patients receiving deterioration of the general conditions associat- linezolid concomitantly with serotonergic drugs ed with pain in the abdomen, the dorsal and lum- [2]. Methadone is a serotonin re-uptake inhibitor bar-sacral spine, and lower limbs two months which may be involved in serotonin toxicity reac- duration, with fatigue, hypotension and oliguria tions [3]. during the last 24 hours reported by his family. To the best of our knowledge, we present the first In previous months, for the persistence of a sciat- reported case of SS associated with linezolid and ica he had taken anti-inflammatory therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, with a self-administration. The Corresponding author patient had a remarkable medical history be- Antonio Mastroianni cause of a surgery for right iliac-femoral arterial E-mail: [email protected] bypass about 1 year ago. The patient assumed 264 A. Mastroianni, et al. methadone 40 mg/day, as maintenance therapy right arm were positive for MRSA. On the basis for opioid dependence. Antiretroviral therapy of blood and pus cultures, on the fifth day of hos- included lamivudine 300 mg daily, tenofovir 245 pitalization antibiotic treatment was changed to mg daily and darunavir 800 mg / ritonavir 100 linezolid 600 mg twice daily plus clindamycin mg daily. 600 mg four times daily intravenously, suspend- On admission, clinical examination revealed a ing the previous antibiotic combination, while dehydrated patient with high fever, blood pres- repeated surgical drainage of the muscle abscess- sure of 90/50 mmHg, heart rate 125/min, and es was performed during his hospital stay. How- respiratory rate 35/min, as well as the presence ever, the patient was febrile (39°C) and sweating of multiple erythematous and tender swellings and three days after the introduction of new anti- over the right elbow and arm, left side of the biotic therapy has become increasingly confused, chest wall, and abdomen. Respiratory examina- disoriented and agitated. His pulse fluctuated tion revealed bilateral coarse crepitations. The between 95 and 120 beats/minute, and his blood neurological examination was negative, the pa- pressure between 110/70 and 100/60 mm Hg. tient was collaborative, oriented and responsive He had a score of 10 on the Glasgow Coma Scale even if very suffering. Laboratory findings in- and was unable to sustain conversation; he had cluded: hematocrit 37.6%, white blood cell count generalised abdominal tenderness. Neurological 15.15×109/l, platelet count 95×109/l, C-reactive examination revealed dilated reactive pupils, an protein 340 mg/l, and creatinine 1.2 mg/dl. The increased tone in both legs, with brisk reflexes chest X-ray displayed bilateral opacities, while and clonus at both ankles but no meningism. In- computed tomography (CT) revealed the pres- vestigations revealed a white cell count of 21.1 x ence of multiple cavitated nodular infiltrates in 109/l, predominantly neutrophils, and a C-reac- both pulmonary fields. Ultrasound of the swell- tive protein of 15 mg/dl. Chest and abdominal ings showed the presence of fluid attenuation X-rays and urine were normal. into the muscles. A transthoracic echocardio- An urgent evaluation raised the suspicion of a gram was negative for endocarditis. Supportive serotonin syndrome and after a neurological con- care, including aggressive rehydration with nor- sultation linezolid was immediately suspended; mal saline and empiric antibiotics (ceftriaxone 2 the patient was subjected to rehydration therapy, g once daily intravenously and amoxicillin and steroids and benzodiazepines, with a progressive potassium clavulanate 1000 mg/200 mg every 8 improvement in the next 48 hours. The patient’s hours daily intravenously) was initiated imme- clinical condition gradually improved and a dif- diately. ferent antibiotic therapy including ciprofloxacin, A CT scan of the abdomen showed multiple mus- 400 mg twice daily intravenously, and rifampi- cle abscesses and a pyomyositis of the left psoas cin 600 mg daily intravenously was reintroduced muscle. The kidneys showed some hypodense on the twelfth day of hospitalization. A repeat- areolas with lamellar morphology, the largest in ed CT of the chest (day 20) showed a significant the middle third of the left kidney (finding com- improvement of the infiltrates, while the muscle patible with areas of initial pyelonephritis). There abscesses had reduced in size. The patient was was also evidence of edematous imbibitions of followed up at the clinic; he received ciproflox- subcutaneous and adipose tissue of the left lower acin 750 mg twice daily plus oral rifampin 600 limb tissue, multifocal dorsal-lumbar chronic os- mg daily for three months, with disappearance teomyelitis and a bilateral abscess in suprapatel- of the muscle abscesses (40 days after his dis- lar recess. Blood cultures obtained on admission charge). were positive for MRSA sensitive to daptomy- cin (MIC<0.25 mg/L), levofloxacin (MIC<=0.12 mg/L), linezolid (MIC<1 mg/L), teicoplanin n DISCUSSION (MIC<=0.5 mg/L), tigecycline (MIC<=0.12 mg/L), rifampicin (MIC<=0.03 mg/L) and van- SS, a potentially life-threatening adverse drug re- comycin (MIC<1 mg/L). Cultures obtained from action caused by excessive serotonergic agonism the blood and the purulent material aspirated in central and peripheral nervous system seroto- after guided drainage from the swelling of the nergic receptors, may be caused by a single or a Serotonin syndrome, linezolid and methadone 265 combination of drugs with serotonergic activity, the oxazolidinone class with weak, nonspecific and it results in a variety of mental, autonomic inhibitor of monoamine oxidase enzymes. Con- and neuromuscular changes, which can range in comitant therapy with an adrenergic or seroto- severity from mild to life-threatening [4,5]. nergic agent or consuming tyramine (>100 mg/ A variety of single or a combination of drugs day) may induce SS [12]. with excessive serotonergic agonism on central In a recent critical review serotonergic agent dose nervous system and peripheral serotonergic re- and duration of coadministration with linezolid ceptors can be involved as a cause of SS, includ- did not appear to influence the occurrence of ing MAOIs, tricyclic antidepressants, selective SS. The Authors stated that time of onset ranges serotonin reuptake inhibitors (SSRIs), opiate an- from <1 to 20 days, and effect resolves in <1 to algesics, over-the-counter cough medicines, an- 5 days after discontinuation of offending agents tibiotics, weight-reduction agents, antiemetics, [3]. SS in a chronic-pain patient receiving concur- antimigraine agents, drugs of abuse, H2-antag- rent methadone, ciprofloxacin, and venlafaxine onist and herbal products) can be involved as a has been reported [13]. cause of SS [5]. In our case report we hypothesized the patient Most cases will involve either an SSRIs or an has suffered from a SS due to the interaction MAOIs and at least one other medication. Most between linezolid and methadone, blocking se- reported cases of SS are in patients using multi- rotonin reuptake and the serotonin presynaptic ple serotonergic drugs or who have had consid- release, causing increased levels of serotonin in erable exposure to a single serotonin-augment- the central nervous system (CNS). ing drug [6]. As a matter of fact, mental, autonomic and neu- Most cases of SS are mild and may be treated romuscular symptoms resolved after discon- by withdrawal of the offending agent and sup- tinuation of
Recommended publications
  • Food and Mood: Eating Plants to Fight the Blues P H Y S I C I a N S C O M M I T T E E F O R R E S P O N S I B L E M E D I C I N E 5 1 0 0 W I S C O N S I N a V E., N
    Food and Mood: Eating Plants to Fight the Blues P H Y S I C I A N S C O M M I T T E E F O R R E S P O N S I B L E M E D I C I N E 5 1 0 0 W I S C O N S I N A V E., N. W., S U I T E 4 0 0 • W A S H I N G T O N, D C 2 0 0 1 6 P H O N E ( 2 0 2 ) 6 8 6 - 2 2 1 0 • F A X ( 2 0 2 ) 6 8 6 - 2 2 1 6 • P C R M @ P C R M . O R G • W W W . PHYSICIANSCOMMITTEE . O R G suffering from depression have elevated levels of an enzyme called monoamine oxidase (MAO).4 This enzyme breaks down serotonin, dopamine, and norepinephrine—neurotransmitters which help regulate mood. High MAO levels lead to low levels of these specific neurotransmitters, causing depression. The phytochemical quercetin, found only in plant foods, acts as an MAO inhibitor.5 Working much like a natural antidepressant, quercetin can increase the amount of serotonin, dopamine, and norepinephrine in the brain. Foods with high levels of quercetin include apples, kale, berries, grapes, onion, and green tea.6 Arachidonic acid, a type of fat found only in animals, serves as a precursor to inflammatory chemicals in our bodies. By eating foods high in arachidonic acid, such as chicken, eggs, and other animal products, we set off a cascade of chemical reactions in our body.
    [Show full text]
  • Antibiotic Practice Change to Curtail Linezolid Use in Pediatric Hospitalized Patients in Hawai‘I with Uncomplicated Skin and Soft Tissue Infections
    Antibiotic Practice Change to Curtail Linezolid Use in Pediatric Hospitalized Patients in Hawai‘i with Uncomplicated Skin and Soft Tissue Infections Cheryl Okado MD and Tori Teramae BS Abstract MRSA coverage, clindamycin became a widely-used antibi- otic for treating uncomplicated SSTIs in children. Following Antimicrobial resistance affects health care providers’ choice of antibiotics increasing clindamycin use, increasing clindamycin resistance in the treatment of skin and soft tissue infections (SSTIs). Based on local was soon noted, particularly in MRSA isolates.2 Prior to 2010, antibiotic susceptibility data showing high clindamycin resistance and high MRSA predominance appeared to peak, and since then it has MRSA prevalence, a change in antibiotic regimen for children hospitalized for 3 uncomplicated SSTIs was instituted in an attempt to curb the use of linezolid. been decreasing. The prevalence of clindamycin-resistant GAS A retrospective chart review was performed on 278 pediatric patients with has been known to vary with time and location with US rates uncomplicated SSTIs hospitalized at Kapi‘olani Medical Center for Women ranging from 4%-41% since the early 2000s.4 and Children in Hawai‘i from May 2014 to April 2015 and November 2015 to October 2016. Data consisted of 12 months of baseline data and 12 In Hawai‘i, methicillin and clindamycin resistance patterns of months of data post-implementation of an antibiotic combination regimen of SA initially followed similar increasing trends. Antibiograms 2 widely-used antibiotics: high-dose cefazolin and high-dose clindamycin. at Hawai‘i’s children’s hospital, Kapi‘olani Medical Center for Practitioners were encouraged to use cefazolin alone if clinical suspicion was high for single-organism infection with group A streptococcus.
    [Show full text]
  • Plasma Dopamine-Beta-Hydroxylase and Platelet Monoamine Oxidase
    Plasma dopamine-beta-hydroxylase and platelet monoamine oxidase activities in pigs with different susceptibility to the malignant hyperthermia syndrome induced by halothane R. Dantzer, F. Hatey, R. M. Bluthé To cite this version: R. Dantzer, F. Hatey, R. M. Bluthé. Plasma dopamine-beta-hydroxylase and platelet monoamine oxidase activities in pigs with different susceptibility to the malignant hyperthermia syndrome induced by halothane. Reproduction Nutrition Développement, 1981, 21 (1), pp.103-108. hal-00897802 HAL Id: hal-00897802 https://hal.archives-ouvertes.fr/hal-00897802 Submitted on 1 Jan 1981 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Plasma dopamine-beta-hydroxylase and platelet monoamine oxidase activities in pigs with different susceptibility to the malignant hyperthermia syndrome induced by halothane R. DANTZER F. HATEY R. M. BLUTHÉ Station de Pharmacologie, LN.R.A., 180, Chemin de Tournefeuille, 31300 Toulouse, France. Summary. Plasma DBH and platelet MAO activities were measured by radioenzymatic assay in 10 Large-White and 20 Piétrain pigs 9 to 11 weeks old. Pi6train pigs within the same litter, challenged by halothane, were classifed as malignant hyperthermia (MH) susceptible or not according to their reaction.
    [Show full text]
  • Catecholamines and the Hydroxylation of Tyrosine in Synaptosomes Isolated from Rat Brain (DOPA/Tyramine/Dopamine/Norepinephrine/Octopamine) M
    Proc. Nat. Acad. Sci. USA Vol. 68, No. 10, pp. 2370-2373, October 1971 Catecholamines and the Hydroxylation of Tyrosine in Synaptosomes Isolated from Rat Brain (DOPA/tyramine/dopamine/norepinephrine/octopamine) M. KAROBATH Psychiatric Research Laboratories, Massachusetts General Hospital, Boston, Mass. 02114 Communicated by Seymour S. Kety, July 16, 1971 ABSTRACT Tyrosine hydroxylase activity of synapto- removing transmitters from an extraneuronal location at the somes isolated from rat brain was examined. A modified synapse, then incubation of synaptosomes with catechol- tritium-displacement assay was used, which allowed the measurement of tyrosine hydroxylase activity without the amines should inhibit the formation of DOPA from tyrosine. addition of either inhibitors of the metabolism of the The experiments demonstrate that tyrosine hydroxylase hydroxylated products or added exogenous cofactor. The activity is affected by catecholamine uptake. The concentra- enzyme activity was strongly inhibited by the addition of tions required to inhibit the synthesis of catechols are in the exogenous catecholamines and 3,4-dihydroxy-L-phenyl- M. alanine. Aromatic amines other than catechols did not range of 10-7 markedly influence tyrosine hydroxylase activity. These MATERIALS AND METHODS in vitro findings support the hypothesis that synthesis of catecholamines is regulated by a mechanism of end- [3,5-H]HifTyrosine (Tracerlab) was purified by column chro- product inhibition at the tyrosine hydroxylase step. matography. Catechol impurities were absorbed on alumina and tritiated water and anions were removed by Synaptosomes are pinched-off nerve endings with relatively columns (8), by non-neuronal elements (1, 2). They absorption on Dowex-50 resin. Tyrosine was eluted from little contamination Dowex-50 with 25 ml of 4 N HCl; after distillation of the eluate contain the enzymes necessary for the synthesis of dopamine (v/v) from tyrosine (3, 4).
    [Show full text]
  • Drug News Nov Issue 25
    D r u g N e w s 藥 物 情 報 Issue No. 25 : November 2011 This is a monthly digest of local and overseas drug safety news and information released in the previous month. For the latest news and information, please refer to public announcements or the website of the Drug Office of the Department of Health (http://www.drugoffice.gov.hk). Safety Update US: Updated information about drug Canada and FDA released similar alerts on the interaction of Zyvox (linezolid) and interaction between methylene blue and serotonin Methylene Blue with serotonergic reuptake inhibitors. At the same time, FDA also released alert on the interaction between linezolid psychiatric medications and serotonin reuptake inhibitors. The news had 20 October 2011 – The Food and Drug been reported in Issue No. 17 and 22 of Drug News Administration (FDA) provided additional respectively. In addition, the Department of Health information about the possible serotonin syndrome (DH) issued press statement on 18 February 2011 in patients taking serotonergic psychiatric and letters were also sent to healthcare professionals medications and linezolid/ methylene blue. It was in February 2011 and July 2011. found that not all serotonergic psychiatric drugs had The product certificate holders of the an equal capacity to cause serotonin syndrome with pharmaceutical products containing methylene blue, use of linezolid/ methylene blue. According to the linezolid and serotonergic psychiatric medications FDA's Adverse Event Reporting System (AERS), have been requested to update the sales pack and/or most cases of serotonin syndrome with linezolid or package insert of these products to include methylene blue occurred in patients taking specific information about the potential drug interactions.
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Oxoglutarate Dehydrogenase Multienzyme Complexes Reconstituted from Recombinant
    *RevisedView metadata, Manuscript citation and (text similar UNmarked) papers at core.ac.uk brought to you by CORE Click here to view linked References provided by Repository of the Academy's Library Formation of reactive oxygen species by human and bacterial pyruvate and 2- oxoglutarate dehydrogenase multienzyme complexes reconstituted from recombinant components Attila Ambrusa, Natalia S. Nemeriab, Beata Torocsika, Laszlo Trettera, Mattias Nilssona, Frank Jordanb, and Vera Adam-Vizia,* aDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary bDepartment of Chemistry, Rutgers, the State University, Newark, NJ 07102, USA *To whom correspondence should be addressed at: Department of Medical Biochemistry, Semmelweis University, 37-47 Tuzolto Street, Budapest, 1094, Hungary. Tel.: +361 266 2773, Fax.: +361 267 0031, E-mail: [email protected] 1 Abstract Individual recombinant components of pyruvate and 2-oxoglutarate dehydrogenase multienzyme complexes (PDHc, OGDHc) of human and Escherichia coli (E. coli) origin were expressed and purified from E. coli with optimized protocols. The four multienzyme complexes were each reconstituted under optimal conditions at different stoichiometric ratios. Binding stoichiometries for the highest catalytic efficiency were determined from the rate of NADH generation by the complexes at physiological pH. Since some of these complexes were shown to possess ‘moonlighting’ activities under pathological conditions often accompanied by acidosis, activities were also determined at pH 6.3. As reactive oxygen species (ROS) generation by the E3 component of hOGDHc is a pathologically relevant feature, superoxide generation by the complexes with optimal stoichiometry was measured by the acetylated cytochrome c reduction method in both the forward and the reverse catalytic directions.
    [Show full text]
  • Frequently Asked Questions on The
    Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World Health Organization (WHO) and is to be read alongside the WHO treatment guidelines for isoniazid-resistant tuberculosis and its online annexes. See Further reading ​ ​ at end for additional resources. Who are the new WHO treatment guidelines for isoniazid-resistant tuberculosis intended for ? ​ ​ The WHO treatment guidelines for isoniazid-resistant tuberculosis are targeted at health care ​ professionals (doctors, nurses) and other staff involved in TB care in both low and high resource settings. The possibility of drug-resistant disease now needs to be entertained whenever treating TB patients. These guidelines provide technical detail which is helpful in making the best-informed decision in clinical practice and programme management. The answers to the frequently asked questions (FAQ) in this document intend to help implementers with common, practical issues that arise when adopting the new guidance. This document complements the WHO guidelines by elaborating further on certain aspects of ​ implementation that were beyond the scope of the guideline itself. What are the main recommendations of these new guidelines ? The new guidelines recommend that patients with confirmed isoniazid-resistant and rifampicin susceptible tuberculosis (abbreviated to Hr-TB) are treated for 6 months with a regimen composed of ​ ​ rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx). The exclusion of rifampicin resistance ahead of start of this regimen is critical. It is further recommended not to add streptomycin (S) or other injectable agents to the treatment regimen.
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • Phenelzine Switching Advice 11 May 2020
    Mental Health Special Interest Group Guidance for switching from phenelzine to another antidepressant The supplier of phenelzine sulphate tablets has notified PHARMAC that they can no longer supply this medication in New Zealand. This is reportedly a global issue so the supplier can no longer guarantee supply of any brand of phenelzine. Supplies of phenelzine tablets are likely to run out by mid-late May 2020. People taking phenelzine should be reviewed and, if appropriate, transitioned to another antidepressant as soon as possible. Phenelzine is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class. The only remaining non-selective irreversible MAOI available in New Zealand is tranylcypromine. Tranylcypromine is a non-hydrazine MAOI and differs significantly from phenelzine in some aspects, as outlined below. Tranylcypromine may be an appropriate alternative antidepressant for some patients ; however, it is important to consider an individual’s physical health and psychiatric history, and whether an MAOI is still appropriate. General practitioners should consult with a psychiatrist regarding treatment options and transition. Reducing and stopping phenelzine The dose of phenelzine should ideally be tapered down over a minimum of four weeks, starting immediately in light of very limited supplies. We acknowledge that a faster taper may be required in some cases due to rapidly declining stock. Irreversible MAOIs are associated with a high risk of discontinuation symptoms, e.g. nightmares, headache, irritability, feeling cold, disorientation, hypomania, nausea, sweating, palpitations, myoclonic jerks and, rarely, catatonia or psychosis. Significant discontinuation symptoms should be closely monitored and managed in consultation with a psychiatrist. It is important to maintain MAOI dietary and co-prescribed medication precautions for at least 14 days after stopping phenelzine.
    [Show full text]
  • Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx
    cancers Article Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx Ping-Ho Chen 1,2,3,4,5,6 , Yen-Yun Wang 1,4,5, Ting-Hsun Lan 1,7 , Leong-Perng Chan 6,8,9 and Shyng-Shiou Yuan 4,5,10,11,12,13,* 1 School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan; [email protected] (P.-H.C.); [email protected] (Y.-Y.W.); [email protected] (T.-H.L.) 2 Institute of Biomedical Sciences, National Sun Yat-Sen University, No. 70 Lienhai Road, Kaohsiung 804201, Taiwan 3 Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912301, Taiwan 4 Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807378, Taiwan 5 Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan 6 Cohort Research Center, Kaohsiung Medical University, Kaohsiung 807378, Taiwan; [email protected] 7 Division of Prosthodontics, Department of Dentistry, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan 8 Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan 9 Department of Otorhinolaryngology-Head and Neck Surgery, Kaohsiung Municipal Ta-Tung Hospital and Citation: Chen, P.-H.; Wang, Y.-Y.; Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan Lan, T.-H.; Chan, L.-P.; Yuan, S.-S. 10 Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan Genetic and Proteinic Linkage of 11 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, MAO and COMT with Oral Kaohsiung 807378, Taiwan 12 Potentially Malignant Disorders and Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan 13 Cancers of the Oral Cavity and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Pharynx.
    [Show full text]
  • ZYVOX (Linezolid) Injection (Linezolid) Tablets (Linezolid) for Oral Suspension
    ® ZYVOX (linezolid) injection (linezolid) tablets (linezolid) for oral suspension To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION ZYVOX I.V. Injection, ZYVOX Tablets, and ZYVOX for Oral Suspension contain linezolid, which is a synthetic antibacterial agent of the oxazolidinone class. The chemical name for linezolid is (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide. The empirical formula is C16H20FN3O4. Its molecular weight is 337.35, and its chemical structure is represented below: O O O N N O C C H N 3 F H ZYVOX I.V. Injection is supplied as a ready-to-use sterile isotonic solution for intravenous infusion. Each mL contains 2 mg of linezolid. Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq per 300-mL bag; 3.3 mEq per 200-mL bag; and 1.7 mEq per 100-mL bag). ZYVOX Tablets for oral administration contain 400 mg or 600 mg linezolid as film-coated compressed tablets. Inactive ingredients are corn starch, microcrystalline cellulose, hydroxypropylcellulose, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and carnauba wax. The sodium (Na+) content is 1.95 mg per 400-mg tablet and 2.92 mg per 600-mg tablet (0.1 mEq per tablet, regardless of strength).
    [Show full text]